08:55 EDT Oncternal Therapeutics trading halted, news pending
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Therapeutics price target lowered to $18 from $19 at H.C. Wainwright
- Oncternal Therapeutics reports Q2 EPS ($2.89 ), consensus ($3.10)
- Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
- ONCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results